AAR Corp. Earnings Call Transcripts
Fiscal Year 2026
-
Record Q4 and FY26 results with double-digit growth in sales, EBITDA, and EPS, driven by strong performance across all segments and successful acquisitions. FY27 guidance calls for continued double-digit sales growth and margin expansion, supported by robust demand and a strong M&A pipeline.
-
Revised summary: The company shifted its portfolio to focus on parts, repair, and software, driving growth in parts distribution and maintenance. Software integration via Trax and acquisitions boost efficiency. Both government and commercial segments show momentum. Margin and cash flow targets will improve with restructuring and OEM partnerships.
-
The company has restructured into four segments, exited non-core businesses, and set ambitious three-year growth and margin targets. Strong aftermarket demand, exclusive OEM partnerships, and digital innovation in software and repair underpin above-market growth, while government and international expansion provide additional runway.
-
2021 saw major progress with COVAXIN and gene therapy programs, increased R&D and G&A expenses, and a strengthened cash position. Regulatory milestones were achieved, and the company is well-funded into Q1 2023, with key clinical data expected in the second half of 2022.
-
Second quarter sales grew 16% year-over-year, led by 29% growth in parts supply and strong performance across all segments. Three strategic acquisitions were completed or announced, supporting expansion in new parts distribution and heavy maintenance. Margin improvement is expected as integration progresses, with full-year sales growth projected near 17%.
-
Strong Q1 results featured 17% organic sales growth and margin expansion, led by parts supply and new distribution wins. Full-year organic sales growth outlook was raised to nearly 10%, with continued investment in inventory, software, and MRO capacity to support future growth.
Fiscal Year 2025
-
The meeting was held virtually, with all business proposals—including director elections, executive compensation, and auditor ratification—approved by strong majorities. No questions were submitted by stockholders during the session.
-
Record fiscal 2025 results featured 20% revenue growth, margin expansion, and strong cash flow. New parts distribution and Trax software drove above-market growth, while portfolio optimization and cost synergies improved profitability.
-
Record Q3 sales and margin expansion were driven by strong growth in commercial and government segments, with notable gains in new parts distribution, repair, and TRAX. Guidance calls for continued sales and margin growth, supported by exclusive agreements and operational efficiencies.
-
Record Q2 sales and earnings driven by strong commercial and government demand, with margin expansion across segments. Strategic divestiture and acquisition integration support future growth, while deleveraging and robust aftermarket conditions provide a positive outlook.
-
Q1 FY25 sales rose 20% to $662M with strong growth in all segments and margin expansion. Recent acquisitions and robust demand in commercial and government markets drove results, while investments in capacity and technology support a positive outlook.
Fiscal Year 2024
-
Record FY 2024 sales and margins were driven by strong demand, strategic acquisitions, and efficiency gains. Updated long-term margin targets reflect the accretive Triumph Product Support acquisition, with continued growth and margin expansion expected in FY 2025.
-
Aviation aftermarket services are seeing robust growth due to strong travel demand and delayed new aircraft deliveries. Recent acquisitions and hangar expansions are set to boost margins and capacity, while digital initiatives and government opportunities offer further upside.